3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
6
Active not recruiting
3
Unknown
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
66
Recurrence
20
Neoplasms, Plasma Cell
8
Primary Myelofibrosis
3
Polycythemia Vera
3
Myeloproliferative Disorders
3
Renal Insufficiency
2
Plasmacytoma
2
Lymphoma, Non-Hodgkin
2
Immunoglobulin Light-chain Amyloidosis
2
Central Nervous System Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Sarcoma, Kaposi
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Neurofibromatosis 1
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Intraocular Lymphoma
1
Hodgkin Disease
1
Glioma
1
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
Bevacizumab
75
pembrolizumab
74
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
pomalidomide
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts